Clinical Trial Update: Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing long-acting injectable cabotegravir with daily oral TDF/FTC for HIV pre-exposure prophylaxis in HIV-uninfected women reports safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-28